ArticleJournal of pharmaceutical health care and sciences2026
Prolongation of prothrombin time-international normalized ratio by concomitant use of warfarin and combination therapy with lenvatinib and pembrolizumab in a patient with renal cell carcinoma on dialysis: a case report.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcquired polycystic kidney disease is associated with an increased risk of developing renal cell carcinoma (RCC), which is commonly observed in patients on dialysis and may present with inferior vena cava tumor thrombus. However, there are no prior reports on the use of warfarin for inferior vena cava tumor thrombus in patients on dialysis with RCC receiving combination therapy with lenvatinib and pembrolizumab. CASE PRESENTATION: We describe a 64-year-old Japanese man with RCC complicated by tumor thrombus extending into the renal vein and inferior vena cava who was undergoing hemodialysis. Warfarin was initiated at 2 mg/day due to the risk of thrombus progression. His baseline prothrombin time-international normalized ratio (PT-INR) was 1.80 before the initiation of combination therapy with lenvatinib and pembrolizumab. After 8 days of warfarin administration, combination therapy with lenvatinib (10 mg/day) and pembrolizumab (200 mg every 3 weeks) was initiated. Nine days later, the PT-INR elevated to 3.02 despite no change in warfarin dose. The patient remained asymptomatic. Adjusting warfarin to 2-2.5 mg/day and close PT-INR monitoring successfully restored values to the therapeutic range of 1.6-2.6 by day 80, without reducing the lenvatinib dose.
conclusionsNeither warfarin nor lenvatinib is eliminated by dialysis; therefore, potential pharmacokinetic interactions should be managed with the same caution as in non-dialysis patients. Concomitant use of warfarin and combination therapy with lenvatinib and pembrolizumab in patients with RCC undergoing hemodialysis may enhance anticoagulant effects via multiple interacting factors, including cytochrome P-450-related interactions, systemic inflammation, and hypoalbuminemia. Therefore, careful follow-up, including shorter intervals between outpatient visits (e.g., weekly monitoring), is essential for safe PT-INR management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.